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Blockade of TGF‑β signaling to enhance
the antitumor response is accompanied
by dysregulation of the functional activity
of CD4+CD25+Foxp3+ and CD4+CD25−Foxp3+
T cells
Magdalena J. Polanczyk1, Edwin Walker1,2, Daniel Haley1, Bella S. Guerrouahen3* and Emmanuel T. Akporiaye1,2*

Abstract
Background: The pleiotropic cytokine, transforming growth factor (TGF)-β, and CD4+CD25+Foxp3+ regulatory T
cells (Tregs) play a critical role in actively suppressing antitumor immune responses. Evidence shows that TGF-β produced by tumor cells promotes tolerance via expansion of Tregs. Our group previously demonstrated that blockade
of TGF-β signaling with a small molecule TGF-β receptor I antagonist (SM16) inhibited primary and metastatic tumor
growth in a T cell dependent fashion. In the current study, we evaluated the effect of SM16 on Treg generation and
function.
Methods: Using BALB/c, FoxP3eGFP and Rag−/− mice, we performed FACS analysis to determine if SM16 blocked
de novo TGF-β-induced Treg generation in vitro and in vivo. CD4+ T cells from lymph node and spleen were isolated
from control mice or mice maintained on SM16 diet, and flow cytometry analysis was used to detect the frequency of
CD4+CD25−FoxP3+ and CD4+CD25+FoxP3+ T cells. In vitro suppression assays were used to determine the ability to
suppress naive T cell proliferation in vitro of both CD4+CD25+FoxP3+ and CD4+CD25−FoxP3+ T cell sub-populations.
We then examined whether SM16 diet exerted an inhibitory effect on primary tumor growth and correlated with
changes in FoxP3+expression. ELISA analysis was used to measure IFN-γ levels after 72 h co-culture of C
 D4+CD25+ T
+
−
cells from tumor-bearing mice on control or SM16 diet with CD4 CD25 T cells from naive donors.
Results: SM16 abrogates TGF-β-induced Treg generation in vitro but does not prevent global homeostatic
expansion of C
 D4+ T cell sub-populations in vivo. Instead, SM16 treatment causes expansion of a population of
+
−
CD4 CD25 Foxp3+ Treg-like cells without significantly altering the overall frequency of Treg in lymphoreplete naive
and tumor-bearing mice. Importantly, both the CD4+CD25−Foxp3+ T cells and the CD4+CD25+Foxp3+ Tregs in mice
receiving SM16 diet exhibited diminished ability to suppress naive T cell proliferation in vitro compared to Treg from
mice on control diet.
Conclusions: These findings suggest that blockade of TGF-β signaling is a potentially useful strategy for blunting
Treg function to enhance the anti-tumor response. Our data further suggest that the overall dampening of Treg function may involve the expansion of a quiescent Treg precursor population, which is CD4+CD25−Foxp3+.
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Background
Compelling evidence gathered in recent years indicates
that transforming growth factor β (TGF-β) plays a central
role in promoting tumor growth, metastasis and invasiveness [1–4]. Due to the broad range of its biological activity, TGF-β acts as both a growth factor for tumor cells
[5–7] and a suppressor of immune cell function [8–11].
Emerging evidence indicates that TGF-β produced by
tumor cells promotes immunological tolerance [12, 13]
via expansion of T regulatory cells (Tregs). The increased
frequency of Treg in patients with cancer can be inversely
correlated with survival [14–20]. TGF-β is known as one
of the key factors responsible for the development and
homeostasis of tolerance [2, 21–25]. Thus, it has become
apparent that elevated levels of TGF-β in cancer patients
and tumor bearing mice may enhance immune tolerance
to tumors by expanding the regulatory T cell compartment and directly inhibiting effector cell mechanisms
from clearing the established tumor. This leads to tumor
evasion and ineffectiveness of immune-based clinical
approaches to boost host immunity.
In our previous studies, we demonstrated that blockade of TGF-β signaling using a small molecule TGF-β
receptor I antagonist (SM16) inhibited primary and
metastatic tumor growth in a T cell dependent fashion
[19, 26]. In the current study, we evaluated the effect of
SM16 on Treg generation and function. We demonstrate
that SM16 abrogates TGF-β-induced Treg generation
in vitro but does not prevent global homeostatic expansion of 
CD4+ T cell subpopulations in vivo. Instead,
SM16 treatment causes expansion of a population of
CD4+CD25−Foxp3+ Treg-like cells without significantly
altering the overall frequency of Treg in lymphoreplete
naive and tumor-bearing mice. Importantly, both the
CD4+CD25−Foxp3+ and the C
 D4+CD25+Foxp3+ T cells
in mice receiving SM16 diet exhibited diminished ability to suppress naive T cell proliferation in an in vitro
assay compared to Treg from mice on control diet. These
findings suggest that blockade of TGF-β signaling is a
potentially useful strategy for eliminating Treg function
to enhance the anti-tumor response. Our data further
suggest that the overall dampening of Treg function may
involve the expansion of a quiescent Treg precursor population, which is CD4+CD25−Foxp3+.
Methods
Reagents

Fluorescein isothiocyanate (FITC), Allophycocyanin cyanine tandem (APC-H7), R-phycoerythrin (PE) or Allophycocyanin (APC)-conjugated monoclonal antibodies
(mAbs) were used for cytofluorometric analysis of antimouse Ki67 (BD PharMingen, San Diego, CA, USA), antimouse CD4, anti-mouse CD25 and anti-mouse FoxP3
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(eBioscience, San Diego, CA). Purified hamster antimouse mAbs, anti-CD3 (clone 145-2C11) and anti-CD28
(clone 37.51) were also purchased from BD Pharmingen.
Recombinant TGF-β was purchased from Peprotech (NJ,
USA). TGF-β neutralizing mAb (1D11) was a gift from
Dr. Hong-Ming Hu (Earle A. Chiles Research Institute,
Portland, OR). Cell enrichment kits for C
 D4+ and Anti−
gen Presenting Cells (APC, CD90.1 ) were purchased
from MACS Miltenyi Biotec Inc., (Auburn, CA, USA).
Dead Fixable Violet Dead Cell Stain Kit was purchased
from Invitrogen (L34955, Carlsbad, CA).
Sm16

SM16 is a novel, orally bioavailable kinase inhibitor that
binds to the ATP-binding pocket of TGF-βR1 (ALK5),
inhibiting its activation [19, 27, 28]. When tested against
a panel of 35 unrelated kinases, SM16 was shown to be
highly selective for ALK5 and only moderately inhibited
the activity of p38α and Raf [29]. SM16 was kindly provided by Biogen Idec (Cambridge, MA, USA) under a
Materials Transfer Agreement. For in vitro studies, SM16
was reconstituted in dimethyl sulfoxide (DMSO) and
used at a final concentration of 10 µM. For the oral treatment studies, mice were put on mouse chow containing
SM16 (0.45 g SM16/kg food) (Research Diets, New Brunswick, NJ, USA). Control mice were kept on nutrientmatched AIN93G diet.
Mice

Six to eight weeks old female BALB/c, C57BL/6, Rag−/−
knockout mice were purchased from the Jackson Laboratory (Bar Harbor, ME). B6.Cg-FoxP3tm2Tch/J (FoxP3eGFP)
were bred in the Animal Facility at the Earle A. Chiles
Research Institute (EACRI), Portland, OR. All mice were
housed at the EACRI Animal Care Facility in accordance
with the Principles of Animal Care (NIH publication no.
85-23, revised 1985). The Institutional Animal Care and
Use Committee (IACUC) of the EACRI approved all protocols in compliance with the Guide for the Care and Use
of Laboratory Animals. All mice were maintained under
specific pathogen-free conditions, fed food and water
ad libitum. Mice were routinely checked for any abnormalities until the experiment was terminated. Euthanasia was performed according to guidelines for carbon
dioxide asphyxiation when tumor burden was excessive
or when mice progressed to a moribund state. No unexpected deaths occurred during this study.
Tumor cell line and tumor induction

The 4T1 tumor cell line is a poorly immunogenic, highly
metastatic variant of 410.4, a tumor subline isolated
from a spontaneous mammary tumor that developed in
a BALB/cfC3H mouse [30]. The 4T1 tumor was chosen
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because it is an aggressive TGF-beta-secreting tumor
[31] that bears a resemblance to human breast cancer [32,
33]. It was originally kindly provided by Dr. Fred Miller
of the Michigan Cancer Foundation (Detroit, MI, USA).
The cells were maintained for a limited time in vitro by
passage in complete Dulbecco’s modified Eagle’s medium
(cDMEM; Lonza, Walkersville, MD, USA), containing
100 U/mL penicillin, 100 mg/mL streptomycin (HyClone
Laboratories, Logan, UT, USA), 0.025 mg/mL amphotericin B (HyClone Laboratories) and 10% fetal bovine
serum (FBS; Lonza). Trypsin-versene mixture was purchased from (BioWhittaker, MD, USA). For tumor induction, cells were detached using trypsin-versene mixture
by incubation for 5 min at 37 °C. Subsequently, cells were
harvested, counted, spun and adjusted to a concentration
of 1 × 106 cells/mL. For tumor induction, 5 × 104 cells (in
50 µL volume) were injected subcutaneously (s.c.) into
the mammary fat pad. When tumors became palpable,
mice were randomized to different groups prior to start
of treatment.
Isolation of spleen, lymph node and tumor‑infiltrating
lymphocytes

Tumor draining inguinal lymph nodes (TDLN) and
spleens were resected and pushed through a 70 μm nylon
sieve (BD Biosciences Discovery Labware, Two Oaks,
CA) to produce a single cell suspension. The cells were
then washed (300×g, 7 min) and filtered through a 40 μm
nylon sieve (BD Biosciences). After red blood cell lysis,
the cells were washed (300×g, 7 min) and filtered through
a 40 μm nylon sieve. To isolate tumor infiltrating immune
cells, tumors were resected and minced using a scalpel
blade in triple enzyme digest mix containing 10 mg/mL
collagenase type IV (Worthington 8 Biochemical Corp.
Lakewood, NJ), 1 mg/mL hyaluronidase (Sigma-Aldrich,
St Louis, MO), 200 μg/mL DNAse I (Roche Applied Sciences, Indianapolis, IN) in Hank’s balanced salt solution
(HBSS, Lonza). The tumors were then incubated with
agitation (37 °C, 45 min). After addition of ethylenediaminetetraacetic acid (EDTA, 10 mM), the digest was
incubated for another 15 min. Subsequently, the digested
tissue was pushed sequentially through 70 μm and 40 μm
nylon sieves, washed (300×g, 7 min), overlaid on Ficoll
(FicoLite-LM, Atlanta Biologicals, Lawrenceville, GA)
and centrifuged (1500×g, 25 min, without brake). The
interface was collected and washed twice (300×g, 7 min).
Cell enrichment

For purification of C
 D4+ T cells, single cell suspensions
of splenocytes were enriched untouched by immunomagnetic bead selection using MACS Miltenyi system (Miltenyi, Auburn, CA, USA) according to the manufacturer’s
protocol Briefly, CD4+ T cells were enriched by depletion
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of magnetically labeled contaminating CD8α+, CD11b+,
CD11c+, CD19+, CD45R (B220)+, CD49b (DX5)+,
CD105+, MHC-class II+, and Ter-119+ (erythroid) cells.
The highly enriched (90%) 
CD4+ T cells were subsequently stained with anti-CD4 and anti-CD25 mAbs,
and, depending on the cell donor, either C
 D4+CD25+
+
+
+
cells (BALB/c), or CD4 CD25 FoxP3 (FoxP3eGFP) cells
were sorted from CD4+CD25– or CD4+CD25–FoxP3−
cells respectively, using a FACSAria sorter (BD Immunocytometry Systems, San Jose, CA). In some experiments,
CD4+CD25–FoxP3+ cells were also enriched. Naive mice
served as donors of responder T cells (CD4+CD25– or
CD4+CD25–GFP–) and CD4+ enrichment was done as
described above. In addition, splenocytes from naive
female mice were also used to prepare APC. Briefly, cells
were incubated on ice for 15 min with anti-CD90.1 PEconjugated microbeads. After wash, cells were sorted
using the MACS magnetic column. The negative fraction
(CD90.1−) was washed, re-suspended at 1 × 106/mL in
cRPMI and irradiated with 30 Gy in a cesium irradiator.
The overall purity of T cell-depleted APC was ~ 80%.
Generation of induced Treg in vitro

For the in vitro induction of Treg cells, 6-well plates were
coated with anti-CD3 and anti-CD28 mAbs 24 h prior to
the assay in PBS at 4 °C. Two different concentration of
Abs were used to induce the activation of naive T cells
and they were respectively: 2 µg of CD3/CD28 per mL or
10 µg of CD3 and 3 µg of CD28 per mL. Subsequently,
plates were rinsed 3 times with fresh PBS and 1 × 106
FACSAria enriched C
 D4+CD25– or 
CD4+CD25–GFP–
T cells were seeded in the plate in the presence of 2 ng/
mL of recombinant TGF-β for 72 h in cRPMI. The TGF-β
neutralizing Ab (1D11) or SM16 was added to some cultures. After 72 h, cells were harvested and washed once
in cRPMI. The cell pellet was reconstituted in 0.2 mL of
cold PBS and FoxP3 expression was determined after
antibody staining.
Adoptive T cell transfer

For adoptive transfer, MACS-enriched 
CD4+ spleen
cells from FoxP3eGFP donors were sorted into
CD4+CD25–GFP– and 
CD4+CD25+GFP+ populations.
6
An average of 5 × 10 CD4+CD25–GFP–cells were transferred i.v. into each Rag−/− recipient. Upon injection,
mice were separated into two groups and maintained
either on vehicle or SM16 diet for up to 21 days.
Flow cytometry

Five-color (FITC, PE, APC, APC-H7, PB) flow cytometry analysis of stained cells was performed to determine FoxP3+ cell frequency, as well as the phenotype and
proliferation of cells isolated from lymph node, spleen
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and tumor in untreated and SM16-treated mice. Briefly,
pooled cells were divided equally (1 × 106 cells per tube)
and washed with PBS and pre-incubated for 30 min at
4 °C with 1 µL of live/dead cell stain kit. Subsequently,
cells were washed twice in staining buffer, and cells isolated from tumors were pre-incubated additionally with
anti-mouse CD16/CD32 (FcBlock, BDPharMingen)
mAb to block non-specific binding to Fc receptors and
extracellular staining for CD4, CD25 was performed for
25 min on ice. After incubation, cells were washed three
times with staining medium and intracellular staining for
FoxP3 and Ki67 was performed using a modified eBioscience protocol. Briefly, cells were fixed for 45 min and
washed twice with 2 mL of eBioscience permeabilization
buffer. The cells were stained for 15 min with Fc-Block
followed 10 min later with fluorescent-labeled antibodies
to Ki67, FoxP3 or proper isotype control. The cells were
then washed twice with 2 mL of permeabilization buffer,
re-suspended in staining buffer and run on an LSRII Flow
cytometer. Data were analyzed on FlowJo software (TreeStar, Inc., Ashland, OR, USA). Data represent 10,000
gated CD4+ T cells unless otherwise noted.

IFN‑γ ELISA

Treg suppression assay

Results

After FACSAria sort of MACS-purified C
 D4+ T cells,
the enriched negative fraction of either CD4+CD25– or
CD4+CD25–GFP– was washed, re-suspended at 1 × 106/
mL in cRPMI. The CD90-depleted irradiated splenocytes of naive mice served as source of APCs. For in vitro
assays, cells were re-suspended in complete Roswell Park
Memorial Institute 1640 medium (cRPMI 1640) containing 100 U/mL penicillin, 100 mg/mL streptomycin
(HyClone Laboratories), 0.025 mg/mL amphotericin B
(HyClone Laboratories), 70 μM β-2-mercaptoethanol
(Sigma-Aldrich), 2 mM l-glutamine (Lonza), 1 mM
sodium pyruvate (Lonza), 1 × nonessential amino
acids (Lonza), 10 mM HEPES (4-(2-hydroxyethyl)1-piperazineethanesulfonic acid; Lonza) and 10% FBS
(Lonza). Suppression assays were performed in 96-well
round-bottomed plates (Becton–Dickinson) in a final
volume of 200 µL per well of cRPMI. Both APC and
responder cells 
(CD4+CD25– or 
CD4+CD25– FoxP3–)
4
were plated at 0.5 × 10 cells per well in triplicates and
suppressor cells 
(CD4+CD25+, CD4+CD25+FoxP3+
+
–
or CD4 CD25 FoxP3+) were added at the following
responder to Treg ratios: 1:0, 1:1, 1:0.5, 1:0.25, 1:0.1 and
0:1. Anti-CD3 antibody was added to each co-culture at
a final concentration of 1 µg per mL. Co-cultures were
incubated for 48 h and [ 3H]-thymidine was added during
the last 12–18 h of culture. Subsequently, the cells were
harvested on glass fiber filters and assessed for uptake of
the labeled thymidine by liquid scintillation counting.

For in vitro assay of IFN-γ secretion, co-cultures of
suppressors and responders were plated at 1:1 ratio in
a 48-well plate. Wells containing only suppressor or
responder cells were included as controls. Cell-free
supernatants were harvested after 72 h and stored frozen at − 20 °C until the cytokine assay was performed.
The amount of IFN-γ was evaluated in triplicate using
the OptEIA ELISA kit (Pharmingen). A standard curve
was generated to evaluate concentrations of IFN-γ in
the samples using GraphPad Prism version 5b software
(GraphPad Software, La Jolla, CA, USA).
Statistical analysis

Statistical significance of differences among data sets
of treatment groups was assessed by Student’s t-test for
pair-wise comparisons or for comparisons of multiple
groups by one-way analysis of variances (ANOVA) with
Tukey’s HSD test to adjust for multiple comparisons. All
analyses were performed using Prism software (GraphPad, San Diego, CA). Probability values (P) of < 0.05 were
considered indicative of significant differences between
data sets.
SM16 inhibits de novo Treg generation in vitro

To determine whether the mechanism by which SM16
induces anti-tumor response involves the inhibition of de
novo Treg generation, we first tested its capacity to block
TGF-β-induced Treg generation from in vitro CD3/
CD28-activated CD4+CD25– and C
 D4+CD25–GFP– T
cells from BALB/c and FoxP3eGFP donors, respectively.
As demonstrated in a representative example (Fig. 1),
TGF-β induces Foxp3 expression in CD3/CD28 activated
T cells (1A, 1D). Treatment with SM16 or TGF-β neutralizing antibody (anti-TGF-β mAb) abrogated TGF-β
-induced conversion to FoxP3 positive cells (1B, 1D).
TCR activation in the absence of TGF-β did not stimulate
FoxP3 expression (1A, 1C). Repeat independent experiments confirmed SM16 blockade of TGF-β-induced Treg
conversion (1E). Similarly, in vitro stimulation of naive
CD4+CD25– cells from transgenic mice expressing a
dominant negative form of TGF-β receptor type II [34]
did not result in Treg conversion (data not shown).
SM16 enhances homeostatic proliferation and induces
a population of CD4+CD25–FoxP3+ cells in vivo

The blockade of TGF-β-induced Treg generation by
SM16, was not unexpected as many studies have documented the key role of TGF-β signaling on induction and
maintenance of Treg [2, 21–25]. However, this is the first
report to demonstrate inhibition of FoxP3 expression
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Fig. 1 FACS data of C
 D4+CD25− or C
 D4+CD25–FoxP3− T cells from spleen of BALB/c and FoxP3eGFP mice. Cells were treated in vitro for 72 h with
CD3/CD28 antibodies as described in the “Methods” section. Plots show CD25-PE on the y-axis and FoxP3-APC or FoxP3eGFP on the x-axis. Quadrant
statistics noted are percent of live CD4+ gate. a–d Mean values of % C
 D4+CD25+Foxp3+ from 5 independent experiments show SM16 effects on
TGF-β-induced Treg conversion (e). Significance between control and experimental groups were determined by Student’s t-test (*, P < 0.05)

among CD4+CD25−FoxP3− cells in vitro by a small molecule TGF-βRI signaling inhibitor. We next wanted to
determine if SM16 could also prevent Treg generation
in vivo. We investigated the effectiveness of systemic
blockade of TGF-βRI signaling on de novo Treg generation in vivo in adoptive transfer studies using RagKO mice
reconstituted with C
 D4+GFP– T cells from FoxP3eGFP

donors. As shown in Fig. 2, all reconstituted mice maintained on SM16 diet demonstrated a statistically significant increase in total C
 D4+ cellularity in the lymph node
and spleen. Calculation of the absolute cell numbers of
different T cell populations revealed a statistically significant increase in Treg cells (CD4+CD25+FoxP3+),
as well as activated 
(CD4+CD25+FoxP3) and naive
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SM16 reduces suppressive activity of C
 D4+CD25+FoxP3+
−
+
and CD4 + CD25 FoxP3 T cells

Fig. 2 Total CD4+ T cell recovery from lymph node and spleen of
RagKO mice reconstituted with CD4+GFP− cells from FoxP3eGFP
donors. The cells were isolated from recipients 21 days after cell
transfer and treatment with SM16. Control mice were maintained
on standard diet. Data presented are mean of 4 independent
experiments. Significance between control and experimental groups
were determined by Student’s t-test

( CD4+CD25–FoxP3–) T cells in both LN and spleen
(Table 1). Since the adoptive transfer studies suggested
that SM16 might induce global T cell proliferation, we
further tested its effect on endogenous T cell proliferation in lymphoreplete mice. SM16 treatment resulted
in increased frequency of CD4+CD25−FoxP3+ T cells
from gated C
 D4+ T cells in both spleen and lymph node
(Fig. 3a). CD4+CD25+FoxP3+ T cells were also significantly increased in spleen cells, and trended higher in
lymph node cells (Fig. 3b).

Although our in vivo data demonstrated that SM16 did
not prevent de novo Treg generation, but instead induced
global expansion of C
 D4+ T cells, we further sought to
determine whether SM16 treatment had an impact on
the function (suppressive activity) of Treg. As shown
in Fig. 4a, CD4+CD25+FoxP3+ T cells enriched from
spleen of mice on control diet were significantly more
efficient at suppressing thymidine uptake by CD3-stimulated responder cells compared to mice on SM16 diet.
Similarly, CD4+CD25−FoxP3+ T cells enriched from
SM16-treated donors demonstrated reduced suppressive
activity as compared to their counterparts on control diet
(Fig. 4b).
SM16 expands F
 oxP3+ cells in tumor bearing mice

We previously demonstrated that 0.45 g/kg-dose of
SM16 dramatically reduces the growth of primary and
metastatic 4T1 tumors [19]. To determine whether
the beneficial anti-tumor effects of SM16 were associated with changes in the Treg compartment, we analyzed the frequency of FoxP3+ cells in the presence or
absence of SM16 in a tumor prevention model in which
mice receiving injection of 4TI cells into the mammary
pad were immediately put on control or SM16 diet. As
in our earlier study, we again showed this dose of SM16
significantly inhibited tumor growth (Fig. 5). The inhibitory effect of SM16 on primary tumor growth was associated with a significant increase in CD4+CD25–FoxP3+
in the spleen but not in the tumor draining lymph nodes
or tumor (Fig. 6a). Notably, there was no increase in

Table 1 The absolute cell number of CD4+ T cell subsets calculated based on flow cytometry analysis of lymph nodes
and spleen of RagKO mice reconstituted with CD4+GFP−T cells and maintained on control or SM16 diet for 21 days
Absolute cell number per mouse (105)
Lymph node
Treatment

Spleen

Control (%)

SM16 (%)

Control (%)

SM16 (%)

1.18 ± 0.5

13.5 ± 1.4

21.7 ± 0.05

88.8 ± 1.90

Total cell recovery
All CD4+
CD4+ CD25+ Foxp3+ (Treg)
+

+

−

+

−

−

CD4 CD25 Foxp3 (activated T cell)
CD4 CD25 Foxp3 (other)

0.1 ± 0.06 (1.4)

0.08 ± 0.04 (8.3)

1.0 ± 0.5 (91.3)

0.4 ± 0.03* (3.6)
#

0.7 ± 0.04 (6.4)
&

12.4 ± 6.3 (90.0)

0.4 ± 0.2 (3.7)

1.6 ± 1.3 (3.9)

19.7 ± 0.01 (94.0)

2.5 ± 1.03a (3.8)

2.5 ± 0.7b (2.7)

83.8 ± 0.01c (93.5)

Absolute numbers (AN) are presented as the mean trait value ± SEM. The % was determined based on average of ANs from 4 independent experiments
*p value ≤ 0.05, as compared to RagkO on control diet
#

&
a
b
c

p value ≤ 0.05, as compared to RagkO on control diet

p value ≤ 0.05, as compared to RagkO on control diet

p value ≤ 0.05, as compared to RagkO on control diet

p value ≤ 0.05, as compared to RagkO on control diet

p value ≤ 0.05, as compared to RagkO on control diet
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Fig. 3 Frequency of CD25−FoxP3+ and C
 D25+FoxP3+ (Treg) cells, respectively among CD4+ cells isolated from lymph node and spleen. Naive
FoxP3eGFP mice were maintained for 14 days on control or SM16 diet. Subsequently, mice were sacrificed, and lymph node and spleen were
isolated to perform flow cytometry analysis. Frequency of CD25−FoxP3+ (a) and C
 D25+FoxP3+ Tregs (b) cells. Data presented are mean values from
eight animals in 2 independent experiments. Significance between control and experimental groups were determined by Student’s t-test

Fig. 4 In vitro suppressive activity of CD4+CD25+FoxP3+ (a) and CD4+CD25−FoxP3+ (b) T cells isolated from naive or SM16 treated FoxP3eGFP
mice. CD4+CD25+FoxP3+ and C
 D4+CD25−FoxP3+ cells from donor mice were obtained by FACS sorting. The activity of isolated cells having
the ability to suppress naive T cell proliferation in an in vitro assay was tested by adding increasing numbers of C
 D4+CD25+FoxP3+ or
CD4+CD25−FoxP3+ T cells to co-cultures of sorted CD4+CD25− (responder cells) and APCs from naive mice in the presence of anti-CD3. After 48 h
the plates were pulsed for 18 h with [3H]-thymidine. Subsequently, the cells were harvested on glass fiber filters and assessed for uptake of the
labeled thymidine by liquid scintillation (4 and 3 independent experiments respectively). Repeat assays of C
 D4+CD25+Foxp3+ cells were performed
+
−
+
using a single batch of naive responder mice. Similarly, repeat assays of C
 D4 CD25 Foxp3 cells were performed using a separate batch of
responder cells from naive mice

 D4+CD25+FoxP3+ T cells in all studied tissues in
C
tumor-bearing (TBM) mice on SM16 diet (Fig. 6b).
SM16 attenuates the suppressive activity of Treg in mice
bearing established tumor

SM16 treatment of tumor-bearing mice resulted
in
reduced
suppressive
activity
of
splenic
C D4+CD25+ cells. As shown in Fig. 7, C D4+CD25+
T cells from spleen of TBM on control diet significantly inhibited proliferation of CD3-stimulated

C D4+CD25− responder cells as compared to SM16-fed
mice. In addition to assessing the ability of C
 D4+CD25+
T cells to inhibit proliferation, we measured their
effect on IFN-γ production by the C
 D4+CD25− naive
responders. Treg, responders and APC (irradiated
CD90-depleted splenocytes) were plated at 1:1:1 ratio.
As shown in Fig. 8, C D4+CD25+ T cells isolated from
spleen of TBM on control diet, significantly reduced
IFN-γ production by responder T cells. In contrast,
co-incubation of responder T cells with C
 D4+CD25+
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Fig. 5 Primary tumor size in SM16-fed and control mice. Data
represent average tumor size from all animals in 3 independent
experiments. Significance between control and experimental groups
was determined by Student’s t-test

T cells isolated from spleen of SM16-fed TBM partially
restored IFN-γ production.

Discussion
CD4+CD25+FoxP3+ regulatory T cells are crucial to the
maintenance of tolerance in normal individuals, and, so
far gathered evidence indicates that presentation and
progression of certain immunological disorders as well as
the progression of cancer may be a function of Treg cell
behavior [35]. Although, the factors regulating this cell
population are still ill defined, it has been shown that
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TGF-β contributes directly to Treg differentiation and/or
function [36]. Thus, TGF-β can be classified as a pro-tolerance agent, and, once present in the tumor microenvironment, it promotes immune tolerance to tumor cells by
several mechanisms including expansion of the regulatory Treg compartment [12, 13]. This phenomenon has
been recently implicated as one of the major factors contributing to immune evasion by tumors [37]. Thus, there
has been a strong interest in finding strategies for blocking TGF-β signaling to overcome peripheral tolerance in
order to enhance antitumor immunity. TGF-β signals
through a heterodimeric receptor complex formed by
association of TGF-βRI and TGF-βRII subunits with
ligand. However, only binding of TGF- β to the TGF-βRI
subunit of the receptor complex activates the intracellular kinase domain, which leads to the phosphorylation
and activation of the Smad protein family and subsequent
regulation of TGF-β-dependent gene expression [38].
Up-regulation of FoxP3 expression and acquisition of the
regulatory phenotype by peripheral T cells is directly
linked to TGF-β-induced Smad signaling [15]. However,
TGF-β signaling blockade initiated by preventing the
binding of ligand to the receptor via the use of antibodies, (antibodies neutralizing TGF-β peptide) or inhibitors
of TGF-βRII activation has only been partially effective,
and the major issue in reducing Treg effects is insufficient
system saturation resulting in leakiness and incomplete
inhibition of Smad signaling. For the above reason, the
utilization of highly selective inhibitors of TGF-βR can
guarantee a more robust inhibition of signaling and effectively prevent changes in gene expression, including the
up-regulation of FoxP3. In the present work, we have

Fig. 6 Frequency of CD4+CD25−FoxP3+ (a) and C
 D4+CD25+FoxP3+ T cells (b) in lymph node, spleen and TIL. Cells were stained with anti-mouse
CD4 and anti-mouse CD25 and after permeabilization, cells were stained additionally with FoxP3. Data represent average of 3 independent
experiments. Significance between control and experimental groups were determined by Student’s t-test
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Fig. 7 Treg having the ability to suppress the proliferation of naive
T cells isolated from spleen of TBM BALB/c mice, fed control or SM16
diet for 19 days. CD4+CD25+ cells from donor mice were obtained
by FACS sorting. The activity of isolated suppressor cells was tested
by adding increasing ratios of CD4+CD25+ T cells to co-cultures of
sorted CD4+CD25− (responder cells) and APCs from naive mice in
the presence of anti-CD3. After 48 h the plates were pulsed for 18 h
with [3H]-thymidine. Subsequently, the cells were harvested on glass
fiber filters and assessed for uptake of the labeled thymidine by liquid
scintillation (3 independent experiments)

Fig. 8 Effect of CD4+CD25+ T cells from TBM on IFN-γ production.
CD4+CD25+ T cells from TBM either on control or SM16 diet were
co-cultured with CD4+CD25− responder T cells from naive donors
(ratio: 1:1) and stimulated with irradiated APC and soluble anti-CD3
mAb. After 72 h supernatants were harvested from the co-cultures
and were analyzed for IFN-γ concentrations. The amounts of IFN-γ
production were evaluated in triplicate using OptEIA ELISA kit
(Pharmingen). The presented value of IFN-γ production corresponds
to 5 × 104 cells. Bars represent mean values ± SEM (n = 3 from a single
experiment). Significance between control and experimental groups
were determined by Student’s t-test

identified SM16, a small molecule TGF-β signaling inhibitor, which binds the ATP pocket of TGF-βR1, and works
as an anti-tolerance regulator of the Treg compartment.
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As shown herein, SM16 directly blocks the in vitro proliferative expansion of C
D4+CD25+FoxP3+ Treg cells
induced by TGF-β from BALB/c splenic CD4+CD25−
precursors (Fig. 1a, b), and from FoxP3eGFP splenic
CD4+CD25−FoxP3− precursors (Fig. 1c, d). Although
SM16 inhibited the Treg inductive effect of TGF-β across
multiple in vitro experiments (Fig. 1e), it did not block
the expansion of Treg in vivo in transfer experiments of
CD4+/GFP− (FoxP3eGFP donors) donor cells transferred
into lymphodepleted RagKO mice, or into lymphoreplete
normal recipient mice. Previous reports have documented the in vivo effects of TGF-β to inhibit IL-2 production and T cell proliferation and differentiation [8,
39–41]. Thus, it was not unexpected that in vivo administration of SM16 would promote a broad homeostatic
expansion of total cellularity in both the lymph nodes
and spleens of recipient mice (Fig. 2); and, which resulted
in statistically significant increases in absolute numbers
of Treg 
(CD4+CD25+FoxP3+), activated T cells
+
(CD4 CD25+FoxP3−) and naive ( CD4+CD25−FoxP3−) T
cells due to the blunting of autologous in vivo TGF-β
effects. Attenuated TGF-β function may thus have
resulted in concomitant increased systemic IL-2 production, and, simultaneously, abrogated Treg function, if not
their frequency, in vivo (Table 1). Notably, in vivo SM16
administration stimulated the significant expansion of
not only Tregs, but also a second “Treg-like” subpopulation (CD4+CD25−FoxP3+) in splenocytes and lymph
node cells of lymphoreplete mice (Fig. 3a, b). Our studies
therefore indicate that SM16 is not sufficient to inhibit
the induction of the regulatory phenotype in activated
cells and prevent expansion of Treg compartment in vivo.
However, although SM16 did not reduce the in vivo frequency and absolute numbers of Treg cells, Treg from
SM16 treated FoxP3eGFP animals showed significantly
lower levels of suppression of CD3 stimulated T cell proliferation compared to Treg from naive untreated controls in a standard Treg functional assay (Fig. 4a).
Similarly, the “Treg-like” ( CD4+CD25−FoxP3+) subpopulation also showed significantly lower levels of suppression in a Treg functional assay (Fig. 4b). The anergy of
Treg subpopulations in SM16 treated normal naive mice
was also reflected in Treg subpopulations examined in
SM16 treated TBM. Thus, although SM16 administration
resulted in significantly inhibited tumor growth (Fig. 5)
and concomitant increase in the 
CD4+CD25−FoxP3+
Treg-like subpopulation (Fig. 6a), it did not significantly
increase the CD4+CD25+FoxP3+ Treg subpopulation in
the spleen, lymph nodes or tumor microenvironment of
TBM (Fig. 6b). Moreover, CD4+CD25+FoxP3+ Treg from
TMB mice fed SM16 were significantly less suppressive
in the standard Treg suppression assay than Treg from
spleens of untreated TMB control mice (Fig. 7). Similarly,
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Treg from SM16 treated TBM were significantly less
effective at suppressing IFN-γ secretion by CD3 activated
T cells in vitro when compared to Treg from non-treated
TBM control mice (Fig. 8). These findings may provide
further explanation for the enhanced IFN-γ production
and antitumor CTL activity in splenocytes from SM16treated mice that we observed in our earlier studies [19,
26]. The blockade of TGF-β signaling has been shown to
restore the frequency, persistence and cytotoxic activity
among CD8+ T cells in various established tumor models, and may work in part by blocking Treg expansion and
activation [42, 43]. Thus, our data suggest that while systemic blockade of TGF-βRI signaling may diminish the
suppressive potential of Treg cells, it does so without
substantially reducing their frequency or absolute numbers in SM16 treated mice. Unexpectedly, our study also
revealed the expansion of a “Treg-like” C
 D4+ subpopulation which lacked CD25 expression but retained FoxP3 in
splenocytes from SM16 treated normal control and
TBM. Although these CD4+CD25−FoxP3+ cells showed
diminished suppressor function comparable to Tregs
(CD4+CD25+FoxP3+) in normal controls, we did not
study them in SM16 treated TBM. However, Bonelli and
co-workers have described significant increases in a
CD4+CD25−FoxP3+ subpopulation which correlates
with progression of disease in SLE patients [44, 45]. Their
detailed phenotype analysis indicated this subpopulation
more closely resembled regulatory T cells rather than
activated T cells; and although they could suppress T cell
proliferation in vitro they could not inhibit IFN-γ production [45]. The report by Bonelli was preceded by several earlier studies, which collectively indicated the
importance of CD25 as a possible activation marker
within Tregs [46–48]. Moreover, loss of CD25 expression
is also thought to be primarily responsible for agedependent functional decline of Treg cells [49, 50]. The
underlying reasons for the observed change in distribution of CD25 expression need further investigation and
are still unknown. The SM16 induced expansion of the
CD4+CD25−FoxP3+subpopulation, which also displayed
a diminished capacity to suppress T cell proliferation, is
of special interest. Previous reports have suggested
TGF-β alone was sufficient in vitro and in vivo to induce
first FoxP3 expression, and subsequently C
 D25+ expression on peripheral TCR activated Treg precursors [14,
15]. However, more recent studies suggest that IL-2 is
also required for TGF-β to trigger naive CD4+CD25−
cells to become CD25+ and express FoxP3 and develop
into fully functional Treg [38, 51]. Thus, it is tempting to
speculate that the C
 D4+CD25−FoxP3+ subpopulation
may represent an expanding precursor pool of Treg
which have been arrested in their differentiation by the
SM16 induced dysregulation of the previously described
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IL-2/TGF-β signaling interaction [52] which may play a
role in inducing fully functional Tregs. This conclusion is
further supported by the observation that majority of
these cells reside within the proliferating K
 i67+ compartment (unpublished data). This hypothesis is also
strengthened by many reports that highly enriched polyclonal CD4+CD25− T cells can convert to CD4+CD25+
T cells in vivo upon homeostatic proliferation in different
lymphopenic models [53, 54]. These newly generated
CD4+CD25+ T cells were shown to be phenotypically
and functionally the same as naturally occurring Tregs.

Conclusions
The present study demonstrated that systemic blockade
of TGF-βR signaling using SM16 does not change in vivo
Treg frequency, and results in the global expansion of
absolute numbers of T cells, including Treg. Notably,
the blockade of normal TGF-β activation is reflected primarily in reduced suppressive activity and the inability
of Treg to inhibit IFN-γ production from effectors cells.
Furthermore, tissue-selective expansion of a subpopulation of “Treg-like” cells (CD4+CD25−FoxP3+) suggests
that SM16 induces a population of cells which might
resemble dysfunctional Treg cells found in both mice and
humans suffering from autoimmune disorder due to the
loss of Treg functionality. Herein, we hypothesize that
these cells may represent a pool of Treg precursors which
are arrested in their normal differentiation pathway and
are not fully functional. Better understanding of how
these cells, which also occur in autoimmune individuals,
may support antitumor immune response in tumor bearing mice and may lead to novel therapeutic approaches
to combat immune evasion by tumors and other diseases.
Abbreviations
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